LENZ Therapeutics (LENZ) Income from Continuing Operations (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Income from Continuing Operations of 42207000.0 for Q1 2026, down 165.34% year-over-year from 64599898.87 in Q1 2025, and down 17.58% quarter-over-quarter from 35896000.0 in Q4 2025.
LENZ Therapeutics (LENZ) Income from Continuing Operations (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Income from Continuing Operations for 7 consecutive years, with 42207000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 165.34% year-over-year to 42207000.0; the TTM figure through Mar 2026 stood at 109715000.0 (down 123.78% YoY), while the FY2025 annual figure was 82127000.0, down 65.02% from the prior year.
- Income from Continuing Operations fell to 42207000.0 in Q1 2026 per LENZ's latest filing, from 35896000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 10215000.0 in Q3 2024 and bottomed at 636449000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 61183647.06 across 5 years, with a median of 18178000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 387.6% — and 2023, when it jumped 92.18%.
- LENZ Therapeutics' Income from Continuing Operations stood at 28346000.0 in 2022, then surged by 35.87% to 18178000.0 in 2023, then soared by 30.4% to 12652000.0 in 2024, then slumped by 183.72% to 35896000.0 in 2025, then fell by 17.58% to 42207000.0 in 2026.
- Business Quant data shows LENZ's Income from Continuing Operations at 42207000.0 in Q1 2026, 35896000.0 in Q4 2025, and 16700000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | -31.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.92 Mn |
| Mar 31, 2026 | -42.21 Mn |
| Dec 31, 2025 | -35.90 Mn |
| Sep 30, 2025 | -16.70 Mn |
| Jun 30, 2025 | -14.91 Mn |
| Mar 31, 2025 | -15.91 Mn |
| Dec 31, 2024 | -12.65 Mn |
| Sep 30, 2024 | -10.22 Mn |
| Jun 30, 2024 | -10.25 Mn |
| Mar 31, 2024 | -16.14 Mn |
| Dec 31, 2023 | -18.18 Mn |
| Sep 30, 2023 | -53.23 Mn |
| Jun 30, 2023 | -49.79 Mn |
| Mar 31, 2023 | -17.43 Mn |
| Dec 31, 2022 | -28.35 Mn |
| Sep 30, 2022 | -34.23 Mn |
| Jun 30, 2022 | -636.45 Mn |
| Mar 31, 2022 | -27.58 Mn |
| Dec 31, 2021 | -20.94 Mn |
| Sep 30, 2021 | -54.99 Mn |